CF
ELVN icon

Corebridge Financial’s Enliven Therapeutics ELVN Stock Holding History

Corebridge Financial’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,925
Closed -$353K – 862
2025
Q1 		$353K Buy
17,925
+425
+2% +$9.15K ﹤0.01% 1771
2024
Q4 		$394K Sell
17,500
-1,321
-7% -$34.2K ﹤0.01% 1805
2024
Q3 		$481K Sell
18,821
-116
-0.6% -$2.69K ﹤0.01% 1757
2024
Q2 		$443K Buy
+18,937
New +$399K ﹤0.01% 1752

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Corebridge Financial's ELVN Position: Q2 2025 in Review

Corebridge Financial sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 17,925 shares — an estimated $353K sold.

Corebridge Financial first reported a position in ELVN in Q2 2024 and held it in 4 quarters. The position peaked at $481K in Q3 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Corebridge Financial reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 17,925 Enliven Therapeutics shares in Q2 2025, an estimated $353K.
  • Corebridge Financial first reported a position in Enliven Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Enliven Therapeutics position peaked at $481K in Q3 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.